A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Who May Qualify: - healthy infants from 6 weeks to 8 weeks of age (both inclusive) - body weight ≥ 3.2 kg - born at full term pregnancy (≥ 37 weeks) - signed willing to sign a consent form by parent(s) or legally acceptable representative(s) Who Should NOT Join This Trial: - Known history of Hib infection, HepB, diphtheria, tetanus, pertussis, or poliomyelitis - Household contact or intimate exposure with a confirmed case of Hib, HepB, diphtheria, pertussis, tetanus or poliomyelitis within 30 days prior to study registration - Known history of SARS-CoV-2 infection - Participant's mother is HepB antigen or HIV positive - Fever ≥ 38.0 C/100.4 F within 3 days prior to enrollment - Vaccination history of non-study vaccines within 30 days prior to enrollment except for pneumococcal conjugate, rotavirus, HepB and Bacillus Calmette Guerin (BCG) - Previous use of any diphtheria, tetanus, pertussis-based combination vaccine(s), Hib conjugate, poliovirus, or combination - Received immunosuppressive agents or other immune-modifying drugs - Previous use of blood or blood-derived products - Any history of allergy (hypersensitivity) to any of the vaccine components - Participation in another interventional clinical trial within 4 weeks of expected first vaccination Always talk to your doctor about whether this trial is right for you.